| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.32 | 0.10 (+8.20%) | 1.02 - 5.25 | 3.0 million (Above Avg) |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 1.22 |
|---|---|
| Previous Close | 1.22 |
| Day's Range | 1.18 - 1.43 |
| Market Cap | 148.7M |
| Avg Volume (10 Day) | 625.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.82 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)
PR Newswire - Monday 05/20/2013 1:30 AM ET
Cell Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Wednesday 05/15/2013 1:30 AM ET
Cell Therapeutics Reports First Quarter 2013 Financial Results
PR Newswire - Thursday 05/02/2013 4:00 PM ET
Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
PR Newswire - Wednesday 04/24/2013 1:30 AM ET
| CTIC | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.80 | |
| LT Debt/Equity | 0.78 | |
| Earnings Yield | -- | |
| Price/Sales | 122.04 |
| Company | Last | Change |
|---|---|---|
| Enzon Pharmaceuticals Inc | 3.14 | +0.32% |
| Pain Therapeutics Inc | 3.08 | +2.33% |
| Omeros Corp | 5.38 | +0.75% |
| ImmunoCellular Therapeutics Ltd | 2.54 | 0.00% |
| Geron Corp | 1.12 | 0.00% |
Data is delayed by at least 15 min.